<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">ChemistrySelect</journal-id><journal-id journal-id-type="iso-abbrev">ChemistrySelect</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2365-6549</journal-id><journal-id journal-id-type="publisher-id">SLCT</journal-id><journal-title-group><journal-title>Chemistryselect</journal-title></journal-title-group><issn pub-type="epub">2365-6549</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1002/slct.202001123</article-id><article-id pub-id-type="publisher-id">SLCT202001123</article-id><article-categories><subj-group subj-group-type="overline"><subject>Full Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Full Papers</subject><subj-group subj-group-type="heading"><subject>Medicinal Chemistry &#x00026; Drug Discovery</subject></subj-group></subj-group></article-categories><title-group><article-title>Synthesis, Spectroscopic Characterizations of Novel Norcantharimides, Their ADME Properties and Docking Studies Against COVID&#x02010;19 M<sup>pr</sup>&#x000b0;</article-title></title-group><contrib-group><contrib id="slct202001123-cr-0001" contrib-type="author" corresp="yes"><name><surname>&#x000d6;zkan</surname><given-names>Hamdi</given-names><prefix>Dr.</prefix></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0794-6942</contrib-id><xref ref-type="aff" rid="slct202001123-aff-0001">
<sup>1</sup>
</xref><address><email>hozkan@edu.tr</email></address></contrib><contrib id="slct202001123-cr-0002" contrib-type="author"><name><surname>Adem</surname><given-names>&#x0015e;evki</given-names><prefix>Assoc.&#x02005;Prof.&#x02005;Dr.</prefix></name><xref ref-type="aff" rid="slct202001123-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="slct202001123-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Chemistry, Faculty of Science</named-content>
<institution>Gazi University</institution>
<postal-code>06500</postal-code>
<city>Ankara</city>
<country country="TR">Turkey</country>
</aff><aff id="slct202001123-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Chemistry, Faculty of Science</named-content>
<institution>&#x000c7;ank&#x00131;r&#x00131; Karatekin University</institution>
<postal-code>18100</postal-code>
<city>&#x000c7;ank&#x00131;r&#x00131;</city>
<country country="TR">Turkey</country>
</aff><pub-date pub-type="epub"><day>12</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="ppub"><day>14</day><month>5</month><year>2020</year></pub-date><volume>5</volume><issue>18</issue><issue-id pub-id-type="doi">10.1002/slct.v5.18</issue-id><fpage>5422</fpage><lpage>5428</lpage><history><date date-type="received"><day>19</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Wiley&#x02010;VCH Verlag GmbH & Co. KGaA, Weinheim <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 Wiley&#x02010;VCH Verlag GmbH &#x00026; Co. KGaA, Weinheim</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:SLCT-5-5422.pdf"/><abstract><title>Abstract</title><p>A series of novel Norcantharimide derivatives were synthesized and their structures were characterized by FTIR, <sup>1</sup>H and <sup>13</sup>C&#x02009;NMR spectroscopy as well as elemental analyses. The absorption, distribution, metabolism and excretion (ADME) properties of the synthesized molecules were investigated. The results obtained in silico demonstrated that these molecules can be considered as orally active drug candidates due to their physicochemical properties. Also, docking studies demonstrated that all derivatives exhibit a good theoretical affinity with MolDock Score in between 124&#x02013;138 against the main protease of Coronavirus Disease 2019 (COVID&#x02010;19 M<sup>pr</sup>&#x000b0;) that caused worldwide epidemics. We believe that newly synthesized norcantharimide derivatives can guide many future studies in organic synthesis, medicine and pharmaceutical applications.</p></abstract><abstract abstract-type="graphical"><p>A series of new novel Norcantharimides have been synthesized and their absorption, distribution, metabolism and excretion (ADME) properties were investigated. The results obtained in silico showed that these molecules can be considered orally active drug candidates, taking into account their physicochemical properties. In addition, placement studies have shown that all derivatives exhibit good theoretical affinity with the 124&#x02013;138 MolDock Score against the main protease of Coronavirus Disease 2019 (COVID&#x02010;19 M<sup>pr</sup>&#x000b0;), which causes worldwide outbreaks.<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="SLCT-5-5422-g009.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="slct202001123-kwd-0001">ADME</kwd><kwd id="slct202001123-kwd-0002">Cantharidin</kwd><kwd id="slct202001123-kwd-0003">COVID-19 M<sup>pr</sup>&#x000b0;</kwd><kwd id="slct202001123-kwd-0004">Drug design</kwd><kwd id="slct202001123-kwd-0005">Medicinal chemistry</kwd><kwd id="slct202001123-kwd-0006">Molecular docking studies</kwd><kwd id="slct202001123-kwd-0007">Norcantharidin</kwd><kwd id="slct202001123-kwd-0008">Norcantharimide</kwd></kwd-group><counts><fig-count count="9"/><table-count count="3"/><ref-count count="27"/><page-count count="7"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 14, 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:05.06.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="slct202001123-self">H. &#x000d6;zkan, &#x0015e;. Adem, <italic>ChemistrySelect</italic>
<bold>2020</bold>, <italic>5</italic>, 5422.</mixed-citation>
</p></notes></front><body><sec id="slct202001123-sec-0001"><label>1</label><title>Introduction</title><p>Cantharidin, which is by blister beetles as a chemical defense against predators, is a toxic monoterpene. It is one of the first pharmacological natural products used by humans. The dried body of Mylabris (<italic>Mylabris phalerata</italic> and <italic>M. cichorii</italic>), the Chinese blister beetle, has been used in Chinese medicine for thousands of years to treat malignant tumors such as hepatoma, breast cancer and colorectal cancer.</p><p>Cantharidin (<bold>1</bold>), a natural compound, has been used by the Chinese people as an anticancer agent for many years in traditional treatment methods.<xref rid="slct202001123-bib-0001" ref-type="ref">1</xref>, <xref rid="slct202001123-bib-0002" ref-type="ref">2</xref>, <xref rid="slct202001123-bib-0003" ref-type="ref">3</xref> However, since it is a natural toxin, it is not used in chemotherapeutic studies today.<xref rid="slct202001123-bib-0004" ref-type="ref">4</xref> Norcantharidin and norcantharimide, which are derivatives of cantharidin, have gained a great interest due to their less toxic effect.<xref rid="slct202001123-bib-0005" ref-type="ref">5</xref> Norcantharidin (<bold>2</bold>) is the demethylated form of cantharidin. Demethylation reduces not only liver toxicity of cantharidine, but also the biological activity of the obtained norcantharidin. Cantharidin and its analogs are potent inhibitor of serine / threonine protein phosphatase 1 and 2&#x02005;A (PP1 and PP2&#x02005;A).<xref rid="slct202001123-bib-0006" ref-type="ref">6</xref>, <xref rid="slct202001123-bib-0007" ref-type="ref">7</xref>, <xref rid="slct202001123-bib-0008" ref-type="ref">8</xref>, <xref rid="slct202001123-bib-0009" ref-type="ref">9</xref> It is found that compounds containing norcantharidin ring inhibited cell proliferation <italic>in</italic>&#x02005;
<italic>vitro</italic> and showed anticancer activity against various cancer cells. Also, current research results show that norcantharimides or isoindole&#x02010;1,3&#x02010;dion derivatives have a much higher anti&#x02010;cancer activity on many other types of cancer. For example, Kose et&#x02005;al. synthesized new norcantharimide derivatives and investigated the cytotoxic activities of these compounds. They reported that the new norcantharimide derivatives show high anticancer activity in lung and breast cancer.<xref rid="slct202001123-bib-0010" ref-type="ref">10</xref>
</p><p>In recent years, many researchs have been carried out about the anti&#x02010;cancer and anti&#x02010;viral effects of cantharidine derivatives. In one of these studies, Cantharidin was used in chemical treatment of viral infection of Molluscum contagiosum (MC) in the skin.<xref rid="slct202001123-bib-0011" ref-type="ref">11</xref> Meanwhile, in another study, it was proposed to use Norcantharidin to inhibit HIV in&#x02005;vitro.<xref rid="slct202001123-bib-0012" ref-type="ref">12</xref> Yet in the literature, no study can be found on the anti&#x02010;viral activity of Norcantharimide derivatives. Also, there is no study on the effect of these compounds on COVID&#x02010;19 M<sup>pr</sup>&#x000b0; has been conducted so far.</p><p>Computer models provide information about the possible effects of the compounds on metabolism and whether they are suitable for begin used as medicine without performing experimental studies. Cheminformatics allows us to understand its pharmacokinetic, physicochemical, solubility, absorption, and similar properties from the chemical structure of a molecule. Many new molecules are synthesized every year in the world. Testing the bioactivity of these molecules as in&#x02005;vitro and in&#x02005;vivo results manifest very high costs. Therefore, ADME and predicting the targets of the molecule have become essential for those sectors in which these molecules can be used.<xref rid="slct202001123-bib-0013" ref-type="ref">13</xref>
</p><p>In this study, novel norcantharimide analog compounds were synthesized. The structures of the synthesized compounds were characterized using spectrometric methods (<sup>1</sup>H, <sup>13</sup>C&#x02010;NMR, IR and Elemental Analysis). Besides, investigation of the physicochemical, pharmacokinetics and Drug&#x02010;likeness properties of the synthesized molecules for oral administration was aimed.</p><p>The COVID&#x02010;19 has infected more than to million people and is spreading at a rapidly speed. Many efforts have been performed by the scientists to develop treatment methods. With this study, we have aimed to contribute these efforts by investigating the interactions of the new norcantharimide derivatives with the potential target protein COVID&#x02010;19 M<sup>pr</sup>&#x000b0;. COVID&#x02010;19 M<sup>pr</sup>&#x000b0; has the main role in the replication and transcription of the Corona virus in the cell. Inhibition of this enzyme may stop the replication and transcription of the corona virus. This development is an important step in the battle against the virus.<xref rid="slct202001123-bib-0014" ref-type="ref">14</xref>
</p></sec><sec id="slct202001123-sec-0002"><label>2</label><title>Results and discussion</title><sec id="slct202001123-sec-0003"><label>2.1</label><title>Chemistry</title><p>For the synthesis of norcantharimide derivatives (<bold>6</bold>&#x02009;
<bold>a</bold>&#x02013;<bold>f</bold>), 2&#x02010;amino&#x02010;1<italic>H</italic>&#x02010;4,7&#x02010;epoxyisoindole&#x02010;1,3(2<italic>H</italic>)&#x02010;dione <bold>(4)</bold> were used as the key compound. This key compound was obtained by reaction of 3a, 4,7,7a&#x02010;tetrahydro&#x02010;4,7&#x02010;epoxyisobenzofuran&#x02010;1,3&#x02010;dione (<bold>3</bold>) with hydrazine hydrate in the presence of methyl alcohol. 3a,4,7,7a&#x02010;tetrahydro&#x02010;4,7&#x02010;epoxyisobenzofuran&#x02010;1,3&#x02010;dione (<bold>3</bold>) was prepared via an exo&#x02010;selective cycloaddition of furan and maleic anhydride (Scheme&#x02005;<xref rid="slct202001123-fig-5001" ref-type="fig">1</xref>).</p><fig fig-type="Scheme" xml:lang="en" id="slct202001123-fig-5001" orientation="portrait" position="float"><label>Scheme 1</label><caption><p>Synthesis of norcantharimide analog compounds.</p></caption><graphic id="nlm-graphic-3" xlink:href="SLCT-5-5422-g008"/></fig><p>The reaction of the appropriate benzoyl chlorides with 2&#x02010;amino&#x02010;1<italic>H</italic>&#x02010;4,7&#x02010;epoxyisoindole&#x02010;1,3(2<italic>H</italic>)&#x02010;dione (<bold>4</bold>) in the presence of THF gave the norcantharimide derivatives in 57&#x02013;65&#x02009;% yield <bold>6</bold>&#x02009;
<bold>a</bold>&#x02013;<bold>f</bold> (Scheme&#x02005;<xref rid="slct202001123-fig-5001" ref-type="fig">1</xref>).</p></sec><sec id="slct202001123-sec-0004"><label>2.2</label><title>The Characterization of compounds</title><p>The structures of the norcantharimide derivatives that we synthesized in our study are similar. Among these molecules, <bold>6</bold>&#x02009;
<bold>b</bold> was chosen as the model molecule. When the IR spectra of the synthesized compounds were investigated, characteristic bands of the expected functional groups were seen. When the FTIR spectrum of the compound <bold>6</bold>&#x02009;
<bold>b</bold> given the structure formula in Figure&#x02005;<xref rid="slct202001123-fig-0002" ref-type="fig">2</xref> is examined, the presence of a single and strong N&#x02212;H band (&#x0223c;3330&#x02005;cm<sup>&#x02212;1</sup>) confirms the presence of the amide. The aromatic C&#x02212;H band was observed at about 3010&#x02005;cm<sup>&#x02212;1</sup>. There are two carbonyl stretches in the spectra of cyclic imides corresponding to in&#x02010;phase and out of phase stretching of two C=O groups. These usually appear from 1730 to 1680&#x02005;cm<sup>&#x02212;1</sup>. In the phthalimide molecule, the splitting between the symmetric and anti&#x02010;symmetric stretching modes is 42&#x02005;cm<sup>&#x02212;1</sup>, with the &#x003c5;<sub>s</sub>(C=O) and &#x003c5;<sub>as</sub>(C=O) appearing as absorptions of medium and very high intensity at 1769 and 1727&#x02005;cm<sup>&#x02212;1</sup>, respectively.<xref rid="slct202001123-bib-0015" ref-type="ref">15</xref>, <xref rid="slct202001123-bib-0016" ref-type="ref">16</xref>
</p><fig fig-type="Figure" xml:lang="en" id="slct202001123-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chemical structures of cantharidin (<bold>1</bold>), norcantharidin (<bold>2</bold>) and norcantharimide (<bold>3</bold>).</p></caption><graphic id="nlm-graphic-5" xlink:href="SLCT-5-5422-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="slct202001123-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Molecular structure of compound <bold>6</bold>&#x02009;
<bold>b</bold>
</p></caption><graphic id="nlm-graphic-7" xlink:href="SLCT-5-5422-g002"/></fig><p>The band in the FTIR spectrum at 1650&#x02005;cm<sup>&#x02212;1</sup> belongs to the C=O stretching mode in the amide group. The C=C aromatic stretching was observed at 1580&#x02005;cm<sup>&#x02212;1</sup>. The C&#x02212;O group was observed at 1100&#x02005;cm<sup>&#x02212;1</sup>. The <sup>1</sup>H&#x02010;NMR spectrum of the compound <bold>6</bold>&#x02009;
<bold>b</bold> in DMSO&#x02010;<italic>d6</italic> is shown in Figure&#x02005;<xref rid="slct202001123-fig-0003" ref-type="fig">3</xref>.
</p><fig fig-type="Figure" xml:lang="en" id="slct202001123-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The <sup>1</sup>H&#x02010;NMR spectrum of compound <bold>6</bold>&#x02009;
<bold>b</bold>
</p></caption><graphic id="nlm-graphic-9" xlink:href="SLCT-5-5422-g003"/></fig><p>The single peak at &#x003b4; 11.40&#x02005;ppm corresponds to hydrogen (<italic>N</italic>&#x02010;H) (1) in the amide group. The double peaks appearing at &#x003b4; 7.93 and 7.64&#x02005;ppm belong to the hydrogens bound to the C8 and C9 carbons in the aromatic ring. Since the aromatic ring is para&#x02010;substituted, the peaks are seen as doublet of doublet. The single peaks at &#x003b4; 6.43 and &#x003b4; 5.25&#x02005;ppm belong to the hydrogens on the C4&#x02010;C5 and C3&#x02010;C6 carbons, respectively. The peaks of the hydrogens on the C2 and C7 carbons are observed singlet at about &#x003b4; 3.17&#x02005;ppm.</p><p>The <sup>13</sup>C&#x02010;APT&#x02009;NMR spectrum of the compound <bold>6</bold>&#x02009;
<bold>b</bold> in DMSO&#x02010;<italic>d6</italic> is shown in Figure&#x02005;<xref rid="slct202001123-fig-0004" ref-type="fig">4</xref>.
</p><fig fig-type="Figure" xml:lang="en" id="slct202001123-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The <sup>13</sup>C&#x02010;APT&#x02009;NMR spectrum of compound <bold>6</bold>&#x02009;
<bold>b</bold>
</p></caption><graphic id="nlm-graphic-11" xlink:href="SLCT-5-5422-g004"/></fig><p>When the <sup>13</sup>C&#x02010;APT&#x02009;NMR spectrum of compound <bold>6</bold>&#x02009;
<bold>b</bold> is investigated, the peak of the carbons in the <bold>C</bold>=O group in the imide ring (C1 and C8) is observed at &#x003b4; 173.9&#x02005;ppm. The peak of the carbonyl carbon (<bold>C</bold>=O) in the amide group (C9) is observed at about &#x003b4; 164.2&#x02005;ppm. The peaks in the range of &#x003b4; 129.4&#x02010;138.1&#x02005;ppm region belong to aromatic Ar&#x02212;C (C10, C11, C12 and C13) carbons. The peak of carbons C4 and C5 is observed at &#x003b4; 136.8&#x02005;ppm. The peaks of carbons C3&#x02010;C6 and C2&#x02010;C7 are observed at &#x003b4; 80.9 and &#x003b4; 45.5&#x02005;ppm, respectively.</p></sec><sec id="slct202001123-sec-0005"><label>2.3</label><title>ADME prediction</title><p>In silico ADME studies were performed to detect some physicochemical properties, such as lipophilicity, water solubility, and pharmacokinetic properties through the login&#x02010;free website http://www.swissadme.ch.<xref rid="slct202001123-bib-0017" ref-type="ref">17</xref> Absorption (% ABS) of compounds from intestinal was figured out by: % ABS=109&#x000d7;(0.345xTopological Polar Surface Area (TPSA)).<xref rid="slct202001123-bib-0018" ref-type="ref">18</xref>
</p><p>ADME prediction study of the designed compounds demonstrated Table&#x02005;<xref rid="slct202001123-tbl-0001" ref-type="table">1</xref>.
</p><table-wrap id="slct202001123-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>ADME results.</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th valign="top" rowspan="1" colspan="1">
<p>ADME properties</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>a</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>b</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>c</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>d</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>e</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>f</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>4</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>Nelfinavir</bold>
</p>
</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">
<p>Molecular weight (g/mol)</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>302.26</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>318.71</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>363.16</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>298.29</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>314.29</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>329.26</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>284.27</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>180.16</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>567.78</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>Num. rotatable bonds</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>0</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>12</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>Num. H&#x02010;bond acceptors</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>5</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>5</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>6</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>5</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>Num. H&#x02010;bond donors</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>Log <italic>S</italic> (ESOL)</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.98</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;2.41</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;2.73</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;2.12</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.89</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.89</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.81</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>0.06</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;6.36</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>WLOGP</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>0.45</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>0.54</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>0.65</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>0.20</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.10</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.20</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.11</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.58</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>4.37</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>MLOGP</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1.52</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1.64</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;2.73</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1.37</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>0.84</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1.04</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1.12</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.39</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3.20</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>TPSA (&#x000c5;<sup>2</sup>)</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>75.71</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>75.21</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>75.71</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>75.21</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>84.94</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>121.53</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>75.71</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>72.63</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>127.20</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>Absorption (&#x02009;% ABS)</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>82</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>83</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>82</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>83</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>80</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>67</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>83</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>84</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>65.115</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>Log <italic>K</italic>
<sub>p</sub> (skin permeation) (cm/s)</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;7.85</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;7.58</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;7.81</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;7.64</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;8.02</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;8.21</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;7.81</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;8.54</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;5.74</p>
</td></tr></tbody></table><permissions><copyright-holder>Wiley&#x02010;VCH Verlag GmbH &#x00026; Co. KGaA</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>SwissADME section gives a physicochemical property of possible oral drug candidates according to five different rules determined by the Lipinski, Ghose, Veber, Egan, and Muegge.<xref rid="slct202001123-bib-0018" ref-type="ref">18</xref>, <xref rid="slct202001123-bib-0019" ref-type="ref">19</xref>, <xref rid="slct202001123-bib-0020" ref-type="ref">20</xref>, <xref rid="slct202001123-bib-0021" ref-type="ref">21</xref> Our compounds have an acceptable pharmacokinetics profile given these drug&#x02010;likeness rules than norcantharidin. Quantitative classes of solubility in the water is defined as insoluble&#x0003c;&#x02212;10&#x0003c;poorly&#x0003c;&#x02212;6&#x0003c;moderately&#x0003c;&#x02212;4&#x0003c;soluble&#x0003c;&#x02212;2&#x0003c;very&#x0003c;0&#x0003c;highly. According to the results, molecule <bold>6</bold>&#x02009;
<bold>e</bold> and <bold>6</bold>&#x02009;
<bold>f</bold> with the result of &#x02212;1.89 is the most soluble in water and is very soluble. Other molecules were classified as soluble with results in the &#x02212;2, &#x02212;3 range. Adding benzene ring to norcantharidin reduced the water solubility of the synthesized compounds. Substitution &#x02212;Cl, &#x02212;Br, and &#x02212;OCH<sub>3</sub> decreased the solubility of the compound <bold>6</bold>. The &#x02212;F and &#x02212;NO<sub>2</sub> groups did not affect the water solubility of this compound.</p><p>The online program displays whether the compounds are suitable for oral administration with the bioavailability radar panel containing physicochemical properties such as flexibility, insolubility, lipophilicity, size, and polarity. Molecules with oral bioavailability have shown in the colored region (Figure&#x02005;<xref rid="slct202001123-fig-0005" ref-type="fig">5</xref>). Results obtained from computational methods showed that our molecules are suitable for oral application like norcantharidin. Except for NO<sub>2</sub> groups, other groups slightly decreased the absorption rate of the modified compounds in the small intestine. The absorption compounds from the small intestine are above 80&#x02009;%, except for the <bold>6</bold>&#x02009;
<bold>a</bold> compound. Therefore, the absorption potential of the compounds has very high.
</p><fig fig-type="Figure" xml:lang="en" id="slct202001123-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Radar related to physicochemical properties and structure of molecules (Criterias: Lipophilicity:&#x02010;0.7 &#x0003c;XLOGP3&#x0003c; +5.0, Size: 150&#x02005;MW 500&#x02005;g/mol, Polarity: 20&#x0003c;TPSA&#x0003c;130&#x02005;&#x000c5;<sup>2</sup>, Insolubility: 0&#x0003c;log S&#x0003c;6, Insaturation, Flexibility: 0.25&#x0003c;rotatable bonds&#x0003c;9)</p></caption><graphic id="nlm-graphic-13" xlink:href="SLCT-5-5422-g005"/></fig><p>Blood&#x02010;Brain Barrier (BBB) diffusion of CNS&#x02010;inactive compounds due to toxicity is a crucial parameter. The fact that newly synthesized compounds do not cross the blood brain&#x02010;barrier makes them a good drug candidate. Cytochromes P450 (CYP) are the major enzymes involved in the metabolic drug elimination.<xref rid="slct202001123-bib-0022" ref-type="ref">22</xref> Their inhibition leads to toxic or other undesirable adverse effects because of the lower clean up and collection of the drug or its metabolites.<xref rid="slct202001123-bib-0023" ref-type="ref">23</xref> Five major isoforms (CYP1&#x02005;A2, CYP2&#x02005;C19, CYP2&#x02005;C9, CYP2D6, CYP3&#x02005;A4) are responsible for the elimination of the majority of therapeutic molecules.<xref rid="slct202001123-bib-0024" ref-type="ref">24</xref> Our derivatives have not demonstrated like compound <bold>4</bold> any inhibition effect on major CYP 450s.</p></sec><sec id="slct202001123-sec-0006"><label>2.4</label><title>Docking studies</title><p>Possible docking modes between compounds and the COVID&#x02010;19 M<sup>pr</sup>&#x000b0; were studied using the Molegro Virtual Docker 7.<xref rid="slct202001123-bib-0025" ref-type="ref">25</xref> The score function used is MolDock score with the coordinates of the position are X: &#x02212;10.85 Y: 15.32, and Z: 68.39 at 120.832&#x02005;&#x000c5;3 volume, 417.28&#x02005;&#x000c5;2 surface, and 0.30 grid resolution. The target the COVID&#x02010;19 M<sup>pr</sup>&#x000b0; (PDB id: 6LU7; Resolution 2.16&#x02005;&#x000c5; were downloaded in pdb format from protein data bank (http://www.rcsb.org/pdb).<xref rid="slct202001123-bib-0026" ref-type="ref">26</xref> Nelfinavir used as positive control.</p><p>Coronavirus caused worldwide epidemics. We tested our compounds against the protease protein of 2019&#x02010;nCoV as In silico. The scores of the steric and hydrogen bond interactions between derivatives and COVID&#x02010;19 M<sup>pr</sup>&#x000b0; presented in Table&#x02005;<xref rid="slct202001123-tbl-0002" ref-type="table">2</xref> and <xref rid="slct202001123-tbl-0003" ref-type="table">3</xref>.
</p><table-wrap id="slct202001123-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>MolDock score, steric interaction and the hydrogen bond energy of the docked compounds.</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead valign="top"><tr><th colspan="2" valign="top" rowspan="1">
<p>Energy overview: Descriptors</p>
</th><th colspan="9" valign="top" rowspan="1">
<p>Total Energy</p>
</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" valign="top" rowspan="1">
<p>&#x02009;</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>Nelfinavir</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>4</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>a</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>b</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>c</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>d</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>e</bold>
</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>f</bold>
</p>
</th></tr></thead><tbody><tr><td rowspan="2" valign="top" colspan="1">
<p>Protein&#x02010;Ligand interactions</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>Protein Ligand Steric (by PLP)</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;169.050</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;77.745</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;118.8</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;116.168</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;123.423</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;116.037</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;116.025</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;123.686</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;112.436</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>Protein Ligand Hydrogen bonds</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;6.261</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.049</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.523</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.164</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.942</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.207</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.616</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;2.291</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.091</p>
</td></tr><tr><td colspan="2" valign="top" rowspan="1">
<p>Internal Ligand interactions</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>22.284</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;6.532</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;5.215</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;10.939</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;11.977</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;10.788</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;8.614</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;11.039</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;10.979</p>
</td></tr><tr><td colspan="2" valign="top" rowspan="1">
<p>MolDock Score</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;146.766</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;85.325</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;124.5</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;128.271</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;137.342</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;128.032</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;126.255</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;137.016</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;124.506</p>
</td></tr></tbody></table><permissions><copyright-holder>Wiley&#x02010;VCH Verlag GmbH &#x00026; Co. KGaA</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><table-wrap id="slct202001123-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>H&#x02010;bonds interacting with COVID&#x02010;19 M<sup>pr</sup>&#x000b0;</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th valign="top" rowspan="1" colspan="1">
<p>No</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>The number of hydrogen bond</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>Energy</p>
</th><th valign="top" rowspan="1" colspan="1">
<p>Length</p>
</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">
<p>Ref. Mol.</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1 2 3 4</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.984251 &#x02212;2.5 &#x02212;2.5 &#x02212;1.68321</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3.18633 2.86281 3.05449 2.80543</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>4</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.04876</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>2.60146</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.522533</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3.12828</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>a</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.16392</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3.10061</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>b</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.94159</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>2.79785</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>c</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.20656</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3.07903</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>d</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.61612</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>3.10632</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>e</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1 2</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;0.656968 &#x02212;1.63358</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>2.4622 2.84309</p>
</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<p>
<bold>6</bold>&#x02009;
<bold>f</bold>
</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>1</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>&#x02212;1.09128</p>
</td><td valign="top" rowspan="1" colspan="1">
<p>2.60589</p>
</td></tr></tbody></table><permissions><copyright-holder>Wiley&#x02010;VCH Verlag GmbH &#x00026; Co. KGaA</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>The 2D animation of hydrogen bond and some steric interactions is shown in Figure&#x02005;<xref rid="slct202001123-fig-0006" ref-type="fig">6</xref>.
</p><fig fig-type="Figure" xml:lang="en" id="slct202001123-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>The 2D animation of hydrogen bond and some steric interactions.</p></caption><graphic id="nlm-graphic-15" xlink:href="SLCT-5-5422-g006"/></fig><p>Our docking analysis indicates that molecules interact with the COVID&#x02010;19 M<sup>pr</sup>&#x000b0; with values between the 124&#x02013;138 MolDock score.</p><p>Derivatives the best binding to COVID&#x02010;19 M<sup>pr</sup>&#x000b0; among the synthesized compounds are <bold>6</bold>&#x02009;
<bold>b</bold> and <bold>6</bold>&#x02009;
<bold>e</bold> (Figure&#x02005;<xref rid="slct202001123-fig-0007" ref-type="fig">7</xref>). Compound <bold>6</bold>&#x02009;
<bold>e</bold> makes two hydrogen bonds with Cys 145, and Tyr 54 and steric interactions with Met 49, and Phe 140. It can be deducted from Figure&#x02005;<xref rid="slct202001123-fig-0006" ref-type="fig">6</xref> that <bold>6</bold>&#x02009;
<bold>a</bold>, <bold>6</bold>&#x02009;
<bold>c</bold>, and <bold>6</bold>&#x02009;
<bold>d</bold> (with Cys 145), <bold>6</bold> and <bold>6</bold>&#x02009;
<bold>b</bold> (with His 164), <bold>6</bold>&#x02009;
<bold>f</bold> (with Glu 166) are formed hydrogen bonds in the ligands&#x02010; COVID&#x02010;19 M<sup>pr</sup>&#x000b0; complex formation. The new analogs significantly enhanced the interaction of cantharidin compounds with COVID&#x02010;19 M<sup>pr</sup>&#x000b0; when compared to cantharidin. Our analogs exhibited more interaction with COVID&#x02010;19 M<sup>pr</sup>&#x000b0; than some drugs such as lopinavir (ABT&#x02010;378), caspofungin acetate, atazanavir, indinavir.<xref rid="slct202001123-bib-0027" ref-type="ref">27</xref> They exhibited a slightly lower affinity compared to the drug nelfinavir. But, as Table&#x02005;<xref rid="slct202001123-tbl-0001" ref-type="table">1</xref> is analyzed, our derivatives have better physicochemical properties than it, and can be modified to more active molecules. These results indicated that newly synthesized cantharidin derivatives can use to design and discover new compounds interacting with COVID&#x02010;19 M<sup>pr</sup>&#x000b0;.
</p><fig fig-type="Figure" xml:lang="en" id="slct202001123-fig-0007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>The binding of compounds <bold>6</bold>&#x02009;
<bold>b</bold> and <bold>6</bold>&#x02009;
<bold>e</bold> to COVID&#x02010;19 M<sup>pr</sup>&#x000b0;.</p></caption><graphic id="nlm-graphic-17" xlink:href="SLCT-5-5422-g007"/></fig></sec></sec><sec id="slct202001123-sec-0007"><label>3</label><title>Conclusion</title><p>In this study, 6 new compounds, which are Norcantharimide analogs were synthesized. The structures of the synthesized compounds were elucidated in detail by the spectroscopic methods (FTIR, <sup>1</sup>H&#x02010; and <sup>13</sup>C&#x02010;APT&#x02009;NMR) and elemental analysis. According to the results of ADME, new molecules have the necessary properties for oral administration. Docking analyses demonstrated that these compounds can interact with COVID&#x02010;19 M<sup>pr</sup>&#x000b0;. Interactions between the COVID&#x02010;19 M<sup>pr</sup>&#x000b0; and the molecule are changed with the exchange of substituted groups. Therefore, we believe that they can be used as leading molecules in further research to develop new molecules that affect COVID&#x02010;19 M<sup>pr</sup>&#x000b0; activity.</p></sec><sec id="slct202001123-sec-0008"><title>Supporting Information Summary</title><p>Experimental procedures for synthesis, of compounds <bold>3</bold>, <bold>4</bold> and <bold>6</bold> (<bold>6</bold>&#x02009;
<bold>a</bold>&#x02013;<bold>f</bold>) are available in supporting information. Also FT&#x02010;IR, <sup>1</sup>H/ <sup>13</sup>C &#x02010;NMR spectra and elemental analysis results of compounds <bold>6</bold>&#x02009;
<bold>a</bold>&#x02013;<bold>f</bold> are available in the Supporting Information.</p></sec><sec sec-type="COI-statement" id="slct202001123-sec-0010"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><p>As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re&#x02010;organized for online delivery, but are not copy&#x02010;edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.</p></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supplementary</p></caption><media xlink:href="SLCT-5-5422-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="slct202001123-sec-0009"><title>Acknowledgements</title><p>
<italic>We would like to thank Prof. Dr. Y&#x00131;lmaz Y&#x00131;ld&#x00131;r&#x00131;r, Prof. Dr. Ali Di&#x0015f;li, Assoc. Prof. Dr. Serkan Yavuz, Research Assistant Do&#x0011f;ukan Doyduk and &#x000d6;yk&#x000fc; G&#x000f6;ktunal&#x00131; for their valuable opinions and advice</italic>.</p></ack><ref-list><ref id="slct202001123-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="slct202001123-cit-0001">
<string-name>
<given-names>G. S.</given-names>
<surname>Wang</surname>
</string-name>, <source xml:lang="en">J. Ethnopharmacol.</source>
<year>1989</year>, <volume>26</volume>, <fpage>147</fpage>&#x02013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">2689797</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="slct202001123-cit-0002">
<string-name>
<given-names>P. Y.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Shi</surname>
</string-name>, <string-name>
<given-names>F. L.</given-names>
<surname>Hsu</surname>
</string-name>, <string-name>
<given-names>C. F.</given-names>
<surname>Chen</surname>
</string-name>, <source xml:lang="en">J. Chin. Chem. Soc.</source>
<year>1998</year>, <volume>45</volume>, <fpage>323</fpage>&#x02013;<lpage>326</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="slct202001123-cit-0003">
<string-name>
<given-names>L.</given-names>
<surname>Nickolls</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Teare</surname>
</string-name>, <source xml:lang="en">Br. Med. J.</source>
<year>1954</year>, <volume>2</volume>, <fpage>1384</fpage>&#x02013;<lpage>1386</lpage>.<pub-id pub-id-type="pmid">13209125</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="slct202001123-cit-0004">
<string-name>
<given-names>D.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Chen</surname>
</string-name>, <source xml:lang="en">Anti-Cancer Agent. Me.</source>
<year>2009</year>, <volume>9</volume>, <fpage>392</fpage>&#x02013;<lpage>396</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="slct202001123-cit-0005">
<string-name>
<given-names>T. A.</given-names>
<surname>Hill</surname>
</string-name>, <string-name>
<given-names>S. G.</given-names>
<surname>Stewart</surname>
</string-name>, <string-name>
<given-names>S. P.</given-names>
<surname>Ackland</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Gilbert</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Sauer</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Sakoff</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>McCluskey</surname>
</string-name>, <source xml:lang="en">Bioorgan. Med. Chem.</source>
<year>2007</year>, <volume>15</volume>, <fpage>6126</fpage>&#x02013;<lpage>6134</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="slct202001123-cit-0006">
<string-name>
<given-names>R. E.</given-names>
<surname>Honkanen</surname>
</string-name>, <source xml:lang="en">FEBS Letters.</source>
<year>1993</year>, <volume>330</volume>, <fpage>283</fpage>&#x02013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">8397101</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="slct202001123-cit-0007">
<string-name>
<given-names>A.</given-names>
<surname>McCluskey</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Walkom</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Bowyer</surname>
</string-name>, <string-name>
<given-names>S. P.</given-names>
<surname>Ackland</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Gardiner</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Sakoff</surname>
</string-name>, <source xml:lang="en">Bioorg. Med. Chem. Lett.</source>
<year>2001</year>, <volume>11,</volume>
<fpage>2941</fpage>&#x02013;<lpage>2946</lpage>.<pub-id pub-id-type="pmid">11677131</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="slct202001123-cit-0008">
<string-name>
<given-names>F.</given-names>
<surname>Massicot</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Dutertre-Catella</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Pham-Huy</surname>
</string-name>, <string-name>
<given-names>X. H.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>H. T.</given-names>
<surname>Duc</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Warnet</surname>
</string-name>, <source xml:lang="en">Bas&#x00131;c. Cl&#x00131;n. Pharmacol.</source>
<year>2005</year>, <volume>96,</volume>
<fpage>26</fpage>&#x02013;<lpage>32</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="slct202001123-cit-0009">
<string-name>
<given-names>Y.</given-names>
<surname>Baba</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Hirukawa</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sodeoka</surname>
</string-name>, <source xml:lang="en">Bioorgan. Med. Chem.</source>
<year>2005</year>, <volume>13</volume>, <fpage>5164</fpage>&#x02013;<lpage>5170</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="slct202001123-cit-0010">
<string-name>
<given-names>A.</given-names>
<surname>Kose</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kaya</surname>
</string-name>, <string-name>
<given-names>N. H.</given-names>
<surname>Kishal&#x00131;</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Akdemir</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>&#x0015e;ahin</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Kara</surname>
</string-name>, <string-name>
<given-names>G. &#x0015e;.</given-names>
<surname>Mohamed</surname>
</string-name>, <source xml:lang="en">Bioorg. Chem.</source>
<year>2020</year>, <volume>94</volume>, <elocation-id>103421</elocation-id>.<pub-id pub-id-type="pmid">31759659</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="slct202001123-cit-0011">
<string-name>
<given-names>G.</given-names>
<surname>Robinson</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Townsend</surname>
</string-name>, <string-name>
<given-names>M. N.</given-names>
<surname>Jahnke</surname>
</string-name>, <source xml:lang="en">Curr. Dermatol. Rep.</source>
<year>2020</year>, <volume>9</volume>, <fpage>83</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="slct202001123-cit-0012">
<string-name>
<given-names>Z. G.</given-names>
<surname>Peng</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>D. Z.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>H. S.</given-names>
<surname>Chen</surname>
</string-name>, <source xml:lang="en">Acta Pharm. Sin. B.</source>
<year>2010</year>, <volume>45</volume>, <fpage>224</fpage>&#x02013;<lpage>227</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="slct202001123-cit-0013">
<string-name>
<given-names>L. L.</given-names>
<surname>Ferreira</surname>
</string-name>, <string-name>
<given-names>A. D.</given-names>
<surname>Andricopulo</surname>
</string-name>, <source xml:lang="en">Drug Discov. Today.</source>
<year>2019</year>, <volume>24</volume>, <fpage>1157</fpage>&#x02013;<lpage>1165</lpage>.<pub-id pub-id-type="pmid">30890362</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="slct202001123-cit-0014">
<string-name>
<given-names>J.</given-names>
<surname>Jin</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Du</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, <source xml:lang="en">Nature,</source> DOI 10.1038/s415860202223.</mixed-citation></ref><ref id="slct202001123-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="slct202001123-cit-0015">
<string-name>
<given-names>S.</given-names>
<surname>Torrico-Vallejos</surname>
</string-name>, <string-name>
<given-names>M. F.</given-names>
<surname>Erben</surname>
</string-name>, <string-name>
<given-names>O. E.</given-names>
<surname>Piro</surname>
</string-name>, <string-name>
<given-names>E. E.</given-names>
<surname>Castellano</surname>
</string-name>, <string-name>
<given-names>C. O.</given-names>
<surname>Della V&#x000e9;dova</surname>
</string-name>, <source xml:lang="en">J. Mol. Struct.</source>
<year>2010</year>, <volume>975</volume>, <fpage>227</fpage>&#x02013;<lpage>233</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="slct202001123-cit-0016">
<string-name>
<given-names>I. G.</given-names>
<surname>Binev</surname>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Stamboliyska</surname>
</string-name>, <string-name>
<given-names>Y. I.</given-names>
<surname>Binev</surname>
</string-name>, <string-name>
<given-names>E. A.</given-names>
<surname>Velcheva</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Tsenov</surname>
</string-name>, <source xml:lang="en">J. Mol. Struct.</source>
<year>1999</year>, <volume>513</volume>, <fpage>231</fpage>&#x02013;<lpage>243</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="slct202001123-cit-0017">
<string-name>
<given-names>A.</given-names>
<surname>Daina</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Michielin</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Zoete</surname>
</string-name>, <source xml:lang="en">SwissADME Sci. Rep-Uk.</source>
<year>2017</year>, <volume>7</volume>, <fpage>42717</fpage>.</mixed-citation></ref><ref id="slct202001123-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="slct202001123-cit-0018">
<string-name>
<given-names>C. A.</given-names>
<surname>Lipinski</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Lombardo</surname>
</string-name>, <string-name>
<given-names>B. W.</given-names>
<surname>Dominy</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>Feeney</surname>
</string-name>, <source xml:lang="en">Adv. Drug Deliver. Rev.</source>
<year>1997</year>, <volume>23</volume>, <fpage>3</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="slct202001123-cit-0019">
<string-name>
<given-names>I.</given-names>
<surname>Muegge</surname>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Heald</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Brittelli</surname>
</string-name>, <source xml:lang="en">J. Med. Chem.</source>
<year>2001</year>, <volume>44</volume>, <fpage>1841</fpage>&#x02013;<lpage>1846</lpage>.<pub-id pub-id-type="pmid">11384230</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="slct202001123-cit-0020">
<string-name>
<given-names>W. J.</given-names>
<surname>Egan</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Merz</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Baldwin</surname>
</string-name>, <source xml:lang="en">J. Med. Chem.</source>
<year>2000</year>, <volume>43</volume>(<issue>21</issue>), <fpage>3867</fpage>&#x02013;<lpage>3877</lpage>.<pub-id pub-id-type="pmid">11052792</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="slct202001123-cit-0021">
<string-name>
<given-names>A. K.</given-names>
<surname>Ghose</surname>
</string-name>, <string-name>
<given-names>V. N.</given-names>
<surname>Viswanadhan</surname>
</string-name>, <string-name>
<given-names>J. J.</given-names>
<surname>Wendoloski</surname>
</string-name>, <source xml:lang="en">J. Comb. Chem.</source>
<year>1999</year>, <volume>1</volume>, <fpage>55</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">10746014</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="slct202001123-cit-0022">
<string-name>
<given-names>D. F.</given-names>
<surname>Veber</surname>
</string-name>, <string-name>
<given-names>S. R.</given-names>
<surname>Johnson</surname>
</string-name>, <string-name>
<given-names>H. Y.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>B. R.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>K. W.</given-names>
<surname>Ward</surname>
</string-name>, <string-name>
<given-names>K. D.</given-names>
<surname>Kopple</surname>
</string-name>, <source xml:lang="en">J. Med. Chem.</source>
<year>2002</year>, <volume>45</volume>, <fpage>2615</fpage>&#x02013;<lpage>2623</lpage>.<pub-id pub-id-type="pmid">12036371</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="slct202001123-cit-0023">
<string-name>
<given-names>P. F.</given-names>
<surname>Hollenberg</surname>
</string-name>, <source xml:lang="en">Drug Met. Rev.</source>
<year>2002</year>, <volume>34</volume>, <fpage>17</fpage>&#x02013;<lpage>35</lpage>.</mixed-citation></ref><ref id="slct202001123-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="slct202001123-cit-0024">
<string-name>
<given-names>J.</given-names>
<surname>Kirchmair</surname>
</string-name>, <string-name>
<given-names>A. H.</given-names>
<surname>G&#x000f6;ller</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Lang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Kunze</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Testa</surname>
</string-name>, <string-name>
<given-names>I. D.</given-names>
<surname>Wilson</surname>
</string-name>, <string-name>
<given-names>R. C.</given-names>
<surname>Glen</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Schneider</surname>
</string-name>, <source xml:lang="en">Nat. Rev. Drug D&#x00131;scov.</source>
<year>2015</year>, <volume>14</volume>, <fpage>387</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">25907346</pub-id></mixed-citation></ref><ref id="slct202001123-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="slct202001123-cit-0025">A. Molegro, (Aarhus C, Denmark), MVD 7.0 Molegro Virtual Docker, DK-8000, <bold>2019</bold>.</mixed-citation></ref><ref id="slct202001123-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="slct202001123-cit-0026">
<string-name>
<given-names>X.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Jin</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Rao</surname>
</string-name>, <source xml:lang="en">Biorxiv.</source> DOI 10&#x02013;1101/20200226964882.</mixed-citation></ref><ref id="slct202001123-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="slct202001123-cit-0027">
<string-name>
<given-names>A.</given-names>
<surname>Contini</surname>
</string-name>, <source xml:lang="en">Chemrxiv.</source> DOI 10&#x02013;26434/chemrxiv.11847381.</mixed-citation></ref></ref-list></back></article>